α-Synuclein Spurs Neuroinflammation Via Microglial LRRK2
The transcription factor NFATc2 mediates this response.
48 RESULTS
Sort By:
The transcription factor NFATc2 mediates this response.
While the FDA weighs aducanumab’s marketing license application, Alzheimer’s researchers agree that the agency’s own statistician correctly assessed the data as weak. Most prefer that one more trial be done.
A panel of experts concludes the evidence for this scary prospect is weak, but recommends neurosurgeons use separate neurosurgical instruments for young and old patients. The experts called for further studies.